Ultrasound contrast agents are liquid suspensions of biocompatible gas-filled microspheres. When injected into a patient’s vein during an ultrasound exam, they flow around the circulatory system, producing enhanced ultrasound reflectivity. CEUS uses special biocompatible ultrasound contrast agents to improve the quality and reliability of ultrasound scans, thereby helping physicians more accurately diagnose medical conditions and monitor therapy.

Contrast Tuned Imaging technology
CnTI™ is Esaote’s advanced technology for Contrast Enhanced Ultrasound (CEUS) Imaging. Based on low mechanical index and real-time scanning, CnTI™ is an ideal way to use second-generation contrast media.

DCTI function
Esaote CnTI™ offers a unique DCTI function which increases its ability to distinguish between a signal coming from static tissue and contrast agent bubbles inside the vessels.

DCTI is designed to:
- Maximize contrast information
- Remove artefacts in the late phase
- Detect information even from low concentrations just 5 minutes after the bolus injection
See the unseen, every time and everywhere with CnTI™

High sensitivity, deep penetration, and top resolution are common characteristics of CnTI™ Technology on Convex, Linear, Phased Array, Endocavity, Transrectal, Intraoperative, and Volumetric probes for a wide range of clinical applications from diagnosis and guidance to follow-up.

Virtual Navigator

Fusion with CnTI™ Volume provides constant CEUS anatomical references with:
- Lesion detection
- Guidance during difficult interventional procedures
- Free hand and motorized 3D capabilities
- No need of second modality
- Pre- and post-treatment evaluation
- Patient follow-up
- Multi-dataset comparison with CT, MRI, PET, and more.

Thank you for considering Esaote. We listen to your needs and work every day to provide the most advanced technologies and the most innovative design for you to excel in patient care.

Technology and features are system/configuration dependent. The use of Contrast Agents in the USA is limited by FDA to the left ventricle opacification and to characterization of focal liver lesions. Specifications subject to change without notice. Information might refer to products or modalities not yet approved in all countries. Product images are for illustrative purposes only. For further details, please contact your Esaote sales representative.

ESAOTE S.p.A
Via Enrico Melen, 77 16152 Genova, ITALY, Tel. +39 010 6547 1, Fax.+39 010 6547 275, info@esaote.com